1.	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Phase: Phase IV Type: Treatment Status: Closed Age: 16 to 65 Sponsor: Other Protocol IDs: MCC-14178, NCT00361140
2.	Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 4 to 70 Sponsor: Other Protocol IDs: CDR0000066968, RP 98-15, RPCI-RP-9815, NCI-V99-1527, NCT00003816
3.	Phase II/III Randomized Study of Processed Versus Unprocessed Unrelated Bone Marrow Transplantation in Patients With Acute or Chronic Leukemia or Myelodysplastic Syndromes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Completed Age: 12 to 50 Sponsor: Other Protocol IDs: CHIMERIC-HM01, WSU-10-02-99-M01-FB, NCT00004255
4.	Stem Cell Transplant for Bone Marrow Failure Syndromes Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 35 and under Sponsor: Other Protocol IDs: MT2000-18, 9504M09637, NCT00176878
5.	Nonmyeloablative Stem Cell Transplant in Elderly Phase: Phase III, Phase II Type: Treatment Status: Completed Age: Over 60 Sponsor: Other Protocol IDs: 012000, NCT00382759
6.	Phase III Randomized Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) vs Fludarabine (FAMP) for Pretreated B-Cell Chronic Lymphocytic Leukemia (Summary Last Modified 05/98) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 79 Sponsor: Protocol IDs: EORTC-06942
7.	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Phase: Phase III Type: Treatment Status: Completed Age: Under 22 Sponsor: NCI Protocol IDs: NCI-2012-01834, 2961, U10CA098543, CDR0000064883, COG-2961, CCG-2961, NCT00002798
8.	Phase III Randomized Study of Chlorambucil Alone Versus Fludarabine With or Without Cyclophosphamide in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: LRF-CLL4, LRG-MRC-LEUK-CLL4, EU-99030, MRC-LEUK-CLL4, NCT00004218, EUDRACT-58585610, ISRCTN58585610
9.	Phase III Randomized Study of Induction Chemotherapy With Cytarabine, Daunorubicin, and Etoposide Versus Fludarabine and Cytarabine and Induction Chemotherapy With Versus Without Filgrastim (G-CSF) or Tretinoin in Patients With High Risk Acute Myeloid Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: MRC-LEUK-AML-HR, EU-20008, NCT00005863
10.	Phase III Randomized Study of Chlorambucil, Mitoxantrone, and Dexamethasone Versus Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Newly Diagnosed Stage III or IV Follicular Non-Hodgkin's Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: BNLI-MCD/FMD, EU-20035, NCT00006250
11.	Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000068650, EORTC-06992-CLL-3, NCT00017108
12.	Phase III Randomized Study of Fludarabine and Cyclophosphamide With or Without Oblimersen (G3139, Genasense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: GENTA-GL303, UCLA-0104008, NCT00024440
13.	Phase III Comparison of CLB vs FAMP in Previously Untreated Patients with Intermediate- and High-Risk (Rai Stages I-IV) B-Cell CLL Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CLB-9011, CAN-NCIC-CL1, E-C9011, SWOG-9108, CALGB-9011, CL1
14.	Phase III Randomized Study of Single-Agent FAMP vs CVP (CTX/VCR/PRED) in Previously Untreated Patients with Stage III/IV Low-Grade non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: EORTC-20921
15.	Total-Body Irradiation With Or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Phase: Phase III Type: Treatment Status: Closed Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1813.00, NCI-2009-01532, P01CA078902, FHCRC-1813.00, 5666, NCT00075478
16.	Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAM314, 2004-000149-39, NCT00086580
17.	FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 102-14, BO17072, NCT00090051
18.	Primary Rituximab and Maintenance Phase: Phase III Type: Treatment Status: Completed Age: over 18 Sponsor: Other Protocol IDs: PRIMA, NCT00140582
19.	Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 17 and under Sponsor: Other Protocol IDs: TRIAL, TRIAL Relapsed AML 2001/01, NCT00186966
20.	Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000454560, GCLLSG-CLL-8, EU-20560, ML17102, GCLLSG-CLL-8/ML17/02, NCT00281918
21.	Phase III Randomized Study of Risk-Adapted Therapy With Fludarabine Versus Observation Only in Patients With Stage 0-II B-Cell Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL1, EU-20548, GCLLSG-138, MEDAC-GCLLSG-CLL1, NCT00262782
22.	Phase III Randomized Study of Fludarabine Versus Chlorambucil as First-Line Therapy in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 65 to 79 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL5, EU-20557, MEDAC-GCLLSG-CLL5, GCLLSG-73, NCT00262795
23.	Phase III Randomized Study of Fludarabine With Versus Without Cyclophosphamide in Patients With Previously Untreated Advanced Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL4, EU-20538, GCLLSG-153, ISRCTN75653261, MEDAC-GCLLSG-CLL4, NCT00276848
24.	Phase III Randomized Study of Fludarabine, Mitoxantrone Hydrochloride, and Cyclophosphamide With Versus Without Filgrastim (G-CSF) in Patients With Relapsed Binet Stage B or C Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL6, EU-20558, AMGEN-GCLLSG-CLL6, MEDAC-GCLLSG-CLL6, NCT00416910
25.	Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NIP-03-007, NCT00254163